PMID- 10423635
OWN - NLM
STAT- MEDLINE
DCOM- 20000124
LR  - 20191103
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 4
IP  - 11-12
DP  - 1997 Nov-Dec
TI  - Effect of prostaglandin E1 on extravascular lung water in patients with severe 
      heart failure.
PG  - 389-93
AB  - Prostaglandin E ( 1 ) (PGE ( 1 ) ) is a naturally occurring paracrine hormone 
      that is used pharmacologically for treatment of peripheral occlusive arterial 
      disease and to maintain ductus-arteriosus patency in neonates with congenital 
      heart disease until the primary condition is operable. PGE ( 1 ) treatment also 
      has been associated with reduction in pulmonary arterial pressure and increase in 
      cardiac output in patients with left ventricular failure. In contrast, in 
      isolated cases, patients with heart failure reportedly have developed pulmonary 
      edema while receiving PGE ( 1 ). Therefore, to better define the effect of PGE ( 
      1 ) in heart failure, this double-blind study investigated the effect of PGE ( 1 
      ) on extravascular lung water in intensive-care patients with severe heart 
      failure (New York Heart Association [NYHA] classes III and IV) and slightly 
      above-normal extravascular lung water. Intravenous infusion of 60 microg PGE ( 1 
      ) (Prostavasin; Schwarz Pharma, Monheim, Germany) over a period of 2 hours caused 
      no significant change in lung water relative to the baseline values (9.8 +/- 4.3 
      mL/kg before the infusion, 9.3 +/- 3.2 mL/kg after 1 hour, and 9.4 +/- 3.5 mL/kg 
      after 2 hours) or to values observed in placebo-treated patients (6.5 +/- 3.3 
      mL/kg before the infusion, 7.1 +/- 2.7 mL/kg after 1 hour, and 7.0 +/- 3.2 mL/kg 
      after 2 hours). Thus, administration of PGE ( 1 ) is unlikely to cause or worsen 
      pulmonary edema in patients with severe heart failure (NYHA classes III and IV).
FAU - Lenz, K
AU  - Lenz K
AD  - Konventspital der Barmherzigen Bruder, Linz, Austria.
FAU - Kranz, A
AU  - Kranz A
FAU - Kramer, L
AU  - Kramer L
FAU - Buder, R
AU  - Buder R
FAU - Schollmayer, E
AU  - Schollmayer E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - F5TD010360 (Alprostadil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alprostadil/*adverse effects
MH  - Double-Blind Method
MH  - Extravascular Lung Water/*drug effects
MH  - Female
MH  - Heart Failure/*complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Edema/*chemically induced
EDAT- 1999/07/29 00:00
MHDA- 1999/07/29 00:01
CRDT- 1999/07/29 00:00
PHST- 1999/07/29 00:00 [pubmed]
PHST- 1999/07/29 00:01 [medline]
PHST- 1999/07/29 00:00 [entrez]
AID - 10.1097/00045391-199711000-00008 [doi]
PST - ppublish
SO  - Am J Ther. 1997 Nov-Dec;4(11-12):389-93. doi: 10.1097/00045391-199711000-00008.